$23.50
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan
METROLAVIN ointment

Instruction manual

For medical use of the drug

Structure:

Active ingredient: 1 g of ointment contains: lidocaine hydrochloride - 40 mg, metronidazole - 20 mg, chloramphenicol - 10 mg;

excipients: macrogol.

Dosage form.

Ointment.

The main physico-chemical properties: ointment from grayish yellow to greenish yellow.

Pharmacotherapeutic group.

Antibiotics and chemotherapeutic agents, combinations. code atx d06c.

Pharmacological properties.

Pharmacodynamics

Ointment Metrolavin is a complex drug that exhibits antimicrobial, locally analgesic and anti-inflammatory properties. Antimicrobial action is provided by metronidazole and chloramphenicol, which exhibit a wide range of antibacterial activity against aerobic and anaerobic microorganisms - pathogens of purulent-necrotic processes: staphylococcus, protea, Pseudomonas aeruginosa, Escherichia coli, Klebsiella, clostridocia, peperothelcida, peperotolecid, pepterecidotam, peperotolecid, pepterecletocide, pepterecletocide, peperothelcide, pepterecletocide, bacterotolecid, peperothelcidum, bacterotole. Due to the local anesthetic of lidocaine, the ointment has a pronounced and prolonged analgesic effect. Macrogols, along with the properties of the base, enhance the penetration of the active components of the ointment into the deeper layers of the skin and exhibit pronounced osmotic activity, which ensures the adsorption of purulent-necrotic masses and exudate from the wound.

The specified set of pharmacological properties ensures the therapeutic effectiveness of Metrolavin ointment for purulent wounds and burns in the first (purulent-necrotic) phase of the wound process, which is accompanied by a pronounced infectious and inflammatory process and pain.

Pharmacokinetics

Not studied.

Clinical characteristics.

Indications.

Treatment of purulent wounds and burns in the purulent-necrotic phase of the wound process caused by aerobic-anaerobic infection; carbuncles, boils, phlegmon in the first phase of the wound healing process (the first day after operations).

Contraindications

Known hypersensitivity to other local amide type anesthetics; derivatives of imidazole, parabens and a similar compound; psoriasis, eczema, fungal skin lesions, active herpes zoster, atopic dermatitis; the third phase of the wound healing process (granulation and proliferation), the third phase (epithelization and scarring) of the wound healing process, hypersensitivity to any of the components of the drug, pregnancy or lactation, and children under 12 years of age.

Special security measures.

Metrolavin ointment should be used with caution in patients with hematopoietic disorders, heart and liver diseases.

When applying the ointment to a wound with a large surface or with prolonged use of the ointment, monitoring of the heart, liver and blood formation is necessary, since the absorption of metronidazole and chloramphenicol ointment into the blood can lead to impaired blood formation, heart and liver function.

Use with caution in acute diseases, debilitated patients, elderly patients, and renal failure.

Ointment in the eyes should be prevented. Do not apply to mucous membranes. The use of the drug can lead to skin sensitization, accompanied by the development of a hypersensitivity reaction with the further use of this drug externally or in the form of systemic dosage forms.

Interaction with other drugs and other types of interactions.

Lidocaine hydrochloride. under the influence of monoamine oxidase inhibitors, an increase in the local anesthetic effect of lidocaine is possible. it is necessary to use with caution in patients who take class I antiarrhythmic drugs (for example, tocainide, mexiletine); other local anesthetics, since there is a risk of cumulative systemic effects.

Metronidazole.When applied topically, interaction with other drugs is unlikely. The use of metronidazole in patients receiving anticoagulant agents can lead to an increase in the time of prothrombin formation. Use with caution with phenobarbital, disulfiram, cimetidine, alcohol.

Chloramphenicol. The combined use of chloramphenicol with erythromycin, oleandomycin, nystatin and levorin increases the antibacterial activity of the drug, and with benzylpenicillin salts it decreases. Chloramphenicol is incompatible with cytostatics, sulfonamides, diphenyl, barbiturates, pyrazolone derivatives and alcohol.

Features of the application.

Use during pregnancy or lactation.

Do not use the drug during pregnancy or lactation.

The ability to influence the reaction rate when driving vehicles or other mechanisms.

Does not affect.

Dosage and administration.

Metrolavin ointment is applied topically after the initial surgical treatment of wounds, which includes the removal of necrotic tissue and purulent exudate, followed by washing the wound with an antiseptic solution. ointment is applied directly to the affected surface once a day or on sterile gauze napkins, which should cover the wound surface, and then apply a sterile dressing. ligation is carried out once a day daily until the wound is completely cleansed of purulent-necrotic masses and before the formation of granulation tissue begins.

For the treatment of skin burns complicated by purulent exudation, Metrolavin ointment is used after the initial cleansing and toilet wounds. Apply the ointment directly to the burn wound, after which apply a sterile dressing, or to a dressing, which then close the wound. Bandaging should be done every other day or once every 2-3 days, depending on the amount of purulent exudate until the wound is completely cleansed and granulation begins to form.

The maximum daily dose of ointment for adults is 75 g, for children from 12 years old - 25 g. The duration of treatment depends on the severity of the disease and is 1-2 weeks. In the case of a deep localization of the infection in the soft tissues, the ointment should be used in conjunction with antibacterial drugs of systemic action.

Children.

Do not use in children under 12 years of age.

Overdose.

With prolonged use, or with improper use and application to affected skin, the concentration of lidocaine in blood plasma may increase.

Adverse Reactions

On the part of the skin: reactions at the site of application, including irritation, itching, swelling at the site of application of the ointment, rash, burning sensation.

From the immune system: hypersensitivity reactions.

Disorders of myocardial metabolism, increased transaminases and impaired hematopoiesis.

When used correctly, the development of systemic adverse reactions is unlikely, since the intake of lidocaine into the systemic circulation is negligible. Systemic adverse reactions associated with lidocaine, identical in manifestations to those associated with local anesthetics of the amide group. Systemic side effects of metronidazole are unlikely because the concentrations achieved as a result of topical administration are very low. During the use of the drug, direct sunlight should be avoided.

Shelf life.

2 years.

Do not use after the expiration date indicated on the package.

Storage conditions.

Store in a refrigerator at a temperature of 2 ° C to 8 ° C.

Keep out of the reach of children.

Packaging.

40 g of ointment in a tube number 1; in a pack of cardboard.

Vacation category.

Over the counter.

Manufacturer.

Pao "chemical farm" red star ".

The location of the manufacturer and the address of the place of business.

Ukraine, 61010, Kharkov, st. Gordienkovo, 1.

Tags: Metrolavin